We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 2,166

Cannabusiness in New Jersey
  • Porzio Bromberg & Newman PC
  • USA, Global
  • December 5 2018

A structured guide to cannabusiness in New Jersey


Clinical trials in Colombia
  • OlarteMoure
  • Colombia, Global
  • December 3 2018

A structured guide to clinical trials in Colombia


Compliance and enforcement in Colombia
  • OlarteMoure
  • Colombia, Global
  • December 3 2018

A structured guide to compliance and dishonest practices in Colombia


Life Sciences: product regulation and liability in Colombia
  • OlarteMoure
  • Colombia, Global
  • December 3 2018

A structured guide to product regulation and liability laws in Colombia


Pharmacovigilance in Colombia
  • OlarteMoure
  • Colombia, Global
  • December 3 2018

A structured guide to Pharmacovigilance in Colombia


Excessive pricing in the pharma sector
  • Van Bael & Bellis
  • European Union, Global
  • November 30 2018

David Hull discusses recent European cases of excessive pricing in the pharma sector.


Key tips for medical device manufacturers
  • Bristows
  • European Union, Global
  • November 30 2018

Hilary Jones shares some key considerations which companies should be aware of when manufacturing medical devices.


Regulating digital health solutions
  • Bristows
  • Global
  • November 30 2018

When does software become a medical device? Hilary Jones outlines how to define and regulate a medical device.


Pfizer/Flynn Pharma and excessive pricing - a case study
  • Van Bael & Bellis
  • European Union, Global
  • November 30 2018

David Hull discusses the implications of Pfizer/Flynn Pharma's successful appeal against a 2016 ruling of excessive pricing.


Cutting the risk of excessive pricing in the pharma sector
  • Van Bael & Bellis
  • European Union, Global
  • November 30 2018

Learn what pharma companies can do to reduce the risk of excessive pricing.